drugset
drugset / Trial / NCT04194801

A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

NCT04194801 ↗

Phase 1/2 Completed 26 enrolled CStone Pharmaceuticals Blueprint Medicines Corporation · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability, pharmacokinetic and efficacy of fisogatinib (formerly known as BLU-554) in combination with CS1001 in patients with locally advanced or metastatic hepatocellular carcinoma (HCC)

Timeline

Start
2019-12-16
Primary completion
2021-10-20
Completion
2021-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Fisogatinib Small molecule 400 mg —
Subject Fisogatinib Small molecule 600 mg —
Subject Sugemalimab Monoclonal antibody 1200 mg —

Indications

hepatocellular carcinoma